Sio Gene Therapies founder Vivek Ramaswamy (JPM20)
April 28, 2022 03:16 AM EDTUpdated 09:02 AM
People
Cell/Gene Tx

Ax­o­vant-turned-Sio ditch­es two re­main­ing pro­grams, lays off most em­ploy­ees and will seek a buy­er

Kyle LaHucik

Senior Reporter

A year and a half ago, Sio Gene Ther­a­pies at­tempt­ed to steer in­to a new his­to­ry, with then-CEO Pa­van Cheru­vu telling End­points News it was …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times